Tendons from Australia's iconic kangaroos are being tested for use in human knee, ankle and shoulder ligament replacement surgery, with some of the country's injury-prone athletes seen as the first few major beneficiaries of the novel treatment, according to the latest research.
The unprecedented study has "early proof of concept testing" that kangaroo tendons are "six times stronger than human cruciate ligament," the University of Sydney said in a statement late Tuesday.
"Kangaroo tendon has a similar composition to humans but is longer and has better mechanical properties, which makes it an exciting natural product that could be used in a range of surgical procedures," said orthopaedic surgeon Nick Hartnell, who heads one of the three industry partners working with the university on the project.
The project includes an investment of 2.4 million Australian dollars ($1.73 million) by the industry partners, with the tendons for the medical graft material salvaged from the kangaroo meat industry and annual culling of the animals.
Another element of the project includes testing and manufacturing the viability of 3D-printed biodegradable screws made from a ceramic material to fix the kangaroo tendon to human bone, said the university.
"Materials used in ligament reconstructions come from three sources: humans, pigs, and synthetic constructs, and each has drawbacks," said the university's Dr Elizabeth Clarke, who is co-leading the kangaroo tendon-testing project.
Pig tissue alone is used for multi-ligament and revision cases, not primary surgeries, according to the researchers.
The medical use of the marsupial tendons could be key in the treatment of injury-prone athletes such as Australian footballer Alex Johnson, Hartnell told local media.
The defender, who damaged one of his knee ligaments on Sunday and could need a sixth knee reconstruction, stands to gain from the kangaroo tendon treatment, said Hartnell.
The next few steps will include making the kangaroo tendons safe and effective for transplantation in humans, said the researchers.
--IANS
pur/bg
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
